{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-23-000029","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.230816+00:00","generated_at":"2026-06-08T18:31:57.336677+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gilead Q3 2023: EPS beats on lower tax; raises full-year product sales guidance","bullets":["Total revenue $7.1B flat YoY; product sales ex-Veklury up 5% to $6.4B.","GAAP diluted EPS $1.73 vs $1.42 YoY; non-GAAP diluted EPS $2.29 vs $1.90.","Biktarvy sales grew 12% to $3.1B; Oncology sales up 33% to $769M.","Full-year product sales guidance raised to $26.7-26.9B; non-GAAP EPS raised to $6.65-6.85.","Veklury sales fell 31% to $636M; R&D expenses rose to $1.5B on clinical activity and magrolimab discontinuations."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-23-000029","json":"https://secwatch.observer/filing/0000882095-23-000029.json","markdown":"https://secwatch.observer/filing/0000882095-23-000029.md","text":"https://secwatch.observer/filing/0000882095-23-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000029/0000882095-23-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000029/gild-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T18:31:57.336677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"27aa29d54b5224d282c760f8ad2c3aaf3f760b6c","claim":"GILEAD SCIENCES, INC. reported the third quarter of 2023 results: revenue $7.1 billion, EPS $1.73.","evidence_excerpt":"Total third quarter 2023 revenue of $7.1 billion was flat compared to the same period in 2022, primarily driven by increased sales in Oncology and HIV, offset by lower Veklury","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000029/0000882095-23-000029-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Revenue","value":"$7.1 billion"},{"label":"EPS","value":"$1.73"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}